Icon (ICLR) Stock Forecast & Price Target

$173.06 -1.99 (-1.14%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$173.04 -0.02 (-0.01%)

As of 07/2/2026 06:50 PM Eastern

Compare

Icon - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
3

Hold
6

Buy
9

Based on 18 Wall Street analysts who have issued ratings for Icon in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 3 have given a sell rating, 6 have given a hold rating, and 9 have given a buy rating for ICLR.

Consensus Price Target

$173.19
0.07% Upside

According to the 18 analysts' twelve-month price targets for Icon, the average price target is $173.19. The highest price target for ICLR is $240.00, while the lowest price target for ICLR is $100.00. The average price target represents a forecasted upside of 0.07% from the current price of $173.06.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Icon and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ICLR Analyst Ratings Over Time

Type	Current Forecast 7/3/25 to 7/3/26	1 Month Ago 6/3/25 to 6/3/26	3 Months Ago 4/4/25 to 4/4/26	1 Year Ago 7/3/24 to 7/3/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	6 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$173.19	$156.44	$148.80	$213.08
Forecasted Upside	0.07% Upside	8.54% Upside	30.31% Upside	42.00% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Icon Stock vs. The Competition

Type	Icon	Medical Companies	Broader Market
Consensus Rating Score	2.33	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	1.00% Upside	719.37% Upside	14.14% Upside
News Sentiment Rating	Positive News See Recent ICLR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/30/2026	Truist Financial 3 of 5 stars	Jailendra Singh 1 of 5 stars	Upgrade	Hold ➝ Buy	$159.00 ➝ $207.00	+19.66%
6/26/2026	Mizuho 4 of 5 stars	Ann Hynes 2 of 5 stars	Boost Target	Outperform	$180.00 ➝ $190.00	+18.04%
6/25/2026	BMO Capital Markets 3 of 5 stars	Sean Dodge Not Rated	Boost Target	Outperform	$160.00 ➝ $187.00	+14.75%
6/25/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$164.00 ➝ $197.00	+24.55%
6/25/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$140.00 ➝ $165.00	+4.32%
6/25/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Halsted Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$126.00 ➝ $185.00	+16.96%
6/25/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$160.00 ➝ $175.00	+10.64%
6/25/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$130.00 ➝ $155.00	-5.28%
6/25/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$168.00 ➝ $186.00	+17.59%
6/25/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ryskin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underperform	$125.00 ➝ $150.00	-5.17%
Get the Latest News and Ratings for ICLR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Icon and its competitors with MarketBeat's FREE daily newsletter.
6/24/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$160.00	+12.15%
6/1/2026	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$164.00	+22.14%
5/29/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Sell (D+) ➝ Sell (D)
5/29/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$165.00	+22.01%
5/28/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Neutral
5/28/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$145.00	+6.18%
2/25/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold ➝ Strong Sell
2/17/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy ➝ Neutral	$100.00	+7.53%
7/25/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ross Muken Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$170.00 ➝ $240.00	+28.37%
5/2/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Sykes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$180.00 ➝ $160.00	+9.30%
1/14/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:47 AM ET.

Should I Buy Icon Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 29, 2026. Please send any questions or comments about these Icon pros and cons to contact@marketbeat.com.

Icon
Bull Case

Here are some ways that investors could benefit from investing in ICON Public Limited:

The current stock price is around $145.00, which reflects a strong market position and potential for growth in the clinical research sector.
ICON Public Limited has received multiple "Buy" ratings from analysts, indicating confidence in the company's future performance and stability.
Institutional investors own a significant 95.61% of the company's stock, suggesting strong backing and confidence from major financial entities.
The company has a diverse service portfolio that includes clinical trial management and regulatory compliance, positioning it well in the growing pharmaceutical and biotechnology industries.
Recent upgrades from various brokerages, including a target price of $145.00 from Leerink Partners, highlight positive sentiment and potential for stock appreciation.

Icon
Bear Case

Investors should be bearish about investing in ICON Public Limited for these reasons:

Some analysts have issued "Sell" ratings, with a consensus price target of $153.00, indicating potential concerns about the stock's future performance.
Recent downgrades from firms like Zacks Research, which lowered the rating to "strong sell," may reflect underlying issues that could affect investor confidence.
Bank of America has restated an "underperform" rating with a price target of $105.00, suggesting that the stock may not perform as well as the market.
Market volatility and economic uncertainties could impact the performance of companies in the clinical research sector, including ICON Public Limited.
Changes in regulatory environments and competition in the pharmaceutical industry may pose risks to ICON's growth and profitability.

ICLR Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Icon is $173.19, with a high forecast of $240.00 and a low forecast of $100.00.

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 3 sell ratings, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ICLR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICLR, but not buy additional shares or sell existing shares.

According to analysts, Icon's stock has a predicted upside of 0.07% based on their 12-month stock forecasts.

Over the previous 90 days, Icon's stock had 2 upgrades and 2 downgrades by analysts.

Icon has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Citigroup, DA Davidson, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, TD Cowen, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Icon more than other "medical" companies. The consensus rating score for Icon is 2.33 while the average consensus rating score for "medical" companies is 2.29. Learn more on how ICLR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Icon Recommendations

This page (NASDAQ:ICLR) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Icon (ICLR) Stock Forecast & Price Target

Icon - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ICLR Analyst Ratings Over Time

ICLR Analyst Recommendations By Month

ICLR Price Targets by Month

Icon Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Icon Stock? ICLR Pros and Cons Explained

Icon
Bull Case

Icon
Bear Case

ICLR Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Icon Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Icon (ICLR) Stock Forecast & Price Target

Icon - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ICLR Analyst Ratings Over Time

ICLR Analyst Recommendations By Month

ICLR Price Targets by Month

Icon Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Icon Stock? ICLR Pros and Cons Explained

Icon Bull Case

Icon Bear Case

ICLR Forecast - Frequently Asked Questions

What is Icon's forecast for 2026?

Should I buy or sell Icon stock right now?

Does Icon's stock price have much upside?

Has Icon been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Icon?

Do Wall Street analysts like Icon more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Icon Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Icon
Bull Case

Icon
Bear Case